These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 20102875)

  • 1. Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Aylward PE; Gallo R; Bode C; Steg G; Steinhubl SR; Montalescot G;
    Am Heart J; 2010 Jan; 159(1):110-6. PubMed ID: 20102875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
    Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
    Montalescot G; Gallo R; White HD; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1083-91. PubMed ID: 19926048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial.
    Gallo R; Steinhubl SR; White HD; Montalescot G;
    Catheter Cardiovasc Interv; 2009 Feb; 73(3):319-25. PubMed ID: 19213086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
    Gibson CM; Murphy SA; Pride YB; Kirtane AJ; Aroesty JM; Stein EB; Ciaglo LN; Southard MC; Sabatine MS; Cannon CP; Braunwald E;
    Am Heart J; 2008 Jan; 155(1):133-9. PubMed ID: 18082504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention.
    Chen WH; Lau CP; Lau YK; Ng W; Lee PY; Yu CM; Ma E
    J Invasive Cardiol; 2002 Aug; 14(8):439-42. PubMed ID: 12147872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
    Montalescot G; Cohen M; Salette G; Desmet WJ; Macaya C; Aylward PE; Steg PG; White HD; Gallo R; Steinhubl SR;
    Eur Heart J; 2008 Feb; 29(4):462-71. PubMed ID: 18276619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction.
    Corpus RA; House JA; Marso SP; Grantham JA; Huber KC; Laster SB; Johnson WL; Daniels WC; Barth CW; Giorgi LV; Rutherford BD
    Am Heart J; 2004 Sep; 148(3):493-500. PubMed ID: 15389238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
    Collet JP; Montalescot G; Golmard JL; Tanguy ML; Ankri A; Choussat R; Beygui F; Drobinski G; Vignolles N; Thomas D
    Am Heart J; 2004 Apr; 147(4):655-61. PubMed ID: 15077081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
    Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and feasibility of early hospital discharge in ST-segment elevation myocardial infarction--a prospective and randomized trial in low-risk primary percutaneous coronary intervention patients (the Safe-Depart Trial).
    Kotowycz MA; Cosman TL; Tartaglia C; Afzal R; Syal RP; Natarajan MK
    Am Heart J; 2010 Jan; 159(1):117.e1-6. PubMed ID: 20102876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of low-dose intravenous enoxaparin and GP IIb/IIIa inhibitor therapy during PCI.
    Carnendran L; Borkowski R; Markabawi B; Warner MF
    J Invasive Cardiol; 2003 May; 15(5):235-8. PubMed ID: 12730628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of patients with prior percutaneous revascularization undergoing repeat coronary intervention (from the PRESTO Trial).
    Arjomand H; Willerson JT; Holmes DR; Bamlet WR; Surabhi SK; Roukoz B; Espinoza A; McClelland RL; McCormick DJ; Goldberg S;
    Am J Cardiol; 2005 Sep; 96(6):741-6. PubMed ID: 16169350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
    Jang IK; Weissman NJ; Picard MH; Zile MR; Pettigrew V; Shen S; Tatsuno J; Hibberd MG; Tzivoni D; Wackers FJ;
    Am Heart J; 2008 Jan; 155(1):113.e1-8. PubMed ID: 18082500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, predictors, and outcomes of post-percutaneous coronary intervention nephropathy in patients with diabetes mellitus and normal baseline serum creatinine levels.
    Roy P; Raya V; Okabe T; Pinto Slottow TL; Steinberg DH; Smith K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jun; 101(11):1544-9. PubMed ID: 18489931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention.
    Aggarwal A; Dai D; Rumsfeld JS; Klein LW; Roe MT
    Am J Cardiol; 2008 May; 101(10):1413-7. PubMed ID: 18471451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The assessment of safety of enoxaparin administration during percutaneous transluminal coronary angioplasty after ticlopidine pretreatment. Application of low molecular weigh heparins in prevention of coronary micro-embolization].
    Dudek D; Zymek P; BartuĊ› S; Dubiel JS
    Przegl Lek; 2001; 58(6):484-6. PubMed ID: 11816736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.